Who are Didroxan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zurampic, Glucophage, Amekrin, Cardizem, Exidine, Duragesic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dichlorophen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Didroxan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Didroxan (DICHLOROPHEN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: dichlorophen. Area: Ophthalmology.

marketed dichlorophen Solute carrier family 22 member 1 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Didroxan (DICHLOROPHEN).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Didroxan TARGET	DICHLOROPHEN		marketed	dichlorophen	Solute carrier family 22 member 1
Zurampic	LESINURAD	Ironwood Pharms Inc	marketed	Urate Transporter 1 Inhibitor	Solute carrier family 22 member 11	2015-01-01
Glucophage	metformin	Generic (originally Merck Serono/Lipha)	marketed	Dipeptidyl Peptidase 4 Inhibitor [EPC]	5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2	1995-03-03
Amekrin	AMSACRINE		marketed	amsacrine	DNA topoisomerase 2-beta, Solute carrier family 22 member 1, DNA topoisomerase II	1987-01-01
Cardizem	diltiazem	Generic (originally Tanabe Seiyaku)	marketed	Calcium channel blocker (non-dihydropyridine, benzothiazepine)	Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1	1982-11-05
Exidine	CHLORHEXIDINE	Molnlycke Hlth	marketed	chlorhexidine	Solute carrier family 22 member 1	1976-01-01
Duragesic	fentanyl	Johnson & Johnson (Janssen Pharmaceutica)	marketed	Synthetic opioid analgesic	D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor	1968-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-01-25 — Duragesic · 10016403 · Formulation · US
2027-01-25 — Duragesic · 8835460 · Formulation · US
2027-01-25 — Duragesic · 9642797 · Formulation · US
2027-01-25 — Duragesic · 9289387 · Formulation · US
2027-01-25 — Duragesic · 8835459 · Formulation · US
2027-01-25 — Duragesic · 10610523 · Formulation · US
2027-01-25 — Duragesic · 9241935 · Formulation · US
2027-01-25 — Duragesic · 9642844 · Formulation · US
2030-04-27 — Duragesic · 8486972 · Formulation · US
2030-04-27 — Duragesic · 8486973 · Method of Use · US

Sponsor landscape (dichlorophen class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Didroxan — Competitive Intelligence Brief. https://druglandscape.com/ci/dichlorophen. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing